Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Genitourinary 2Other solid neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Solid Tumours 1Solid Tumor 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Liver Neoplasms 1Immunoproliferative Disorders 1Immune System Diseases 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1Advanced Solid Tumor 1Adenocarcinoma 1

Interventions

pembrolizumab 5Nivolumab 2Ipilimumab 2obinutuzumab 1naptumomab estafenatox 1epacadostat 1enzalutamide 1entinostat 1durvalumab 1PM 01183 1Megestrol Acetate 1Levoleucovorin 1Leucovorin 1Irinotecan 1Interleukin-2 1Fentanyl 1Docetaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × enzalutamide × Other solid neoplasm × Clear all
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡